Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.

Pharmacological reports : PR - 1 Oct 2021

Sridharan Kannan, Al Banna Rashed, Malalla Zainab, Husain Aysha, Sater Mai, Jassim Ghufran, Otoom Sameer

Abstract excerpt

BACKGROUND: Warfarin is the most commonly evaluated drug in pharmacogenetic-guided dosing studies. However, gaps remain regarding the influence of the genetic polymorphisms of CYP2C9, VKORC1, and CYP4F2 on specific pharmacodynamic parameters like the warfarin sensitivity index (WSI), prothrombin time international normalized ratio (PT-INR), and log-INR variability. METHODS: A cross-sectional study was conducted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P450 Family 4

Share to Dose-Response Relationship, Drug

Share to Gene Expression Regulation, Enzymologic

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 33811620
DOI: 10.1007/s43440-021-00256-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.PMID 33811620Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.Semantic proximity Read ↗

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.Semantic proximity Read ↗

Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.Semantic proximity Read ↗

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.Semantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.Semantic proximity Read ↗

Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Semantic proximity Read ↗

Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotype distribution in Asian countries.Semantic proximity Read ↗

A multi-factorial analysis of response to warfarin in a UK prospective cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.